
The Skyrizi approval pairs an interleukin-23 antibody with an on-body injector for 720 mg subcutaneous induction in adults, per phase 3 AFFIRM data.
Serono, Inc. (Rockland, MA, www.serono.com) has named Paul Lammers, MD, as its US Chief Medical Officer.
Serono, Inc. (Rockland, MA,






